Getting Your Patient Started
Getting patients started with a MIRAPEX trial prescription package
Patients should be started on a trial prescription for the first two dosage strengths of MIRAPEX:
Ascending Dosage Schedule of MIRAPEX for RLS9
†If needed
- MIRAPEX tablets should be taken once daily, 2 to 3 hours before bedtime
- MIRAPEX may be taken with or without food
- Recommended starting dose is 0.125 mg once daily
- If needed, dose may be increased every 4 to 7 days
- Clinical trials included up to 0.75 mg per day
- There is no evidence that the 0.75 mg dose provides additional benefit beyond the 0.5 mg dose
- In RLS patients with severe and moderate renal impairment (creatinine clearance 20-60 mL/min), the duration between titration steps should be increased to 14 days
Tracking RLS symptoms
It is important that healthcare providers instruct patients to track their symptoms during titration. This will help determine which MIRAPEX dosage is right for an individual. The MIRAPEX trial prescription package contains a helpful tool to assist patients with tracking their symptoms:
An RLS Doctor Discussion Guide/Patient Symptom & Sleep Diary to help patients track their symptoms for dosage purposes
Download a PDF
If you don't have Acrobat® Reader®, click here for a free and secure download.
Download tools to educate patients about Restless Legs Syndrome (RLS) and MIRAPEX. Find out more
Download tools to educate patients about Restless Legs Syndrome (RLS) and MIRAPEX. Find out more

MIRAPEX is now indicated for moderate-to-severe primary Restless Legs Syndrome.
MIRAPEX is now indicated for moderate-to-severe primary Restless Legs Syndrome. Learn more

IMPORTANT SAFETY INFORMATION ABOUT MIRAPEX: MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
MIRAPEX may cause patients to fall asleep without any warning, even while doing normal daily activities, such as driving. When taking MIRAPEX, hallucinations may occur and sometimes patients may feel dizzy, sweaty or nauseated upon standing up. The most common side effects in clinical trials for RLS were nausea, headache, and tiredness. Patients should talk with their doctor if they experience these problems.
Patients and caregivers should be informed that impulse control disorders/compulsive behaviors may occur while taking medicines, including pramipexole, to treat Parkinson's disease and RLS.
This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.
Please see full Prescribing Information, including patient information.

